Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sanofi Consumer Healthcare India PB Ratio?
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR -0.18%21 PB Ratio is 30.53 as of Aug. 01, 2026, which is 23% below its 10-year median of 39.69. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 921 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks worse than 98.05% on this metric.
NSE:SANOFICONR'
s PB Ratio Range Over the Past 10 Years
Min: 24.22 Med: 39.69 Max: 48.05
Current: 30.51
During the past 3 years, Sanofi Consumer Healthcare India's highest PB Ratio was 48.05. The lowest was 24.22. And the median was 39.69.
NSE:SANOFICONR's PB Ratio is ranked worse than 98.05% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs NSE:SANOFICONR: 30.51
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sanofi Consumer Healthcare India PB Ratio Related Terms
Sanofi Consumer Healthcare India PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SANOFICONR vs LLY, JNJ, ABBV: PB Ratio Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's PB Ratio falls into.
Sanofi Consumer Healthcare India PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a PB Ratio of 30.53 as of Aug. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi Consumer Healthcare India and its competitors. This is 23% below median its historical median of 39.69. Over the past decade, Sanofi Consumer Healthcare India's PB Ratio has ranged from 24.22 to 48.05. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #903 out of 921 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is Sanofi Consumer Healthcare India's PB Ratio too high?
Sanofi Consumer Healthcare India's current PB Ratio of 30.53 is 23% below median its 10-year median of 39.69. Over the past 10 years, this metric has ranged from a low of 24.22 to a high of 48.05. The Drug Manufacturers industry median PB Ratio is 1.88. Sanofi Consumer Healthcare India's value of 30.53 is 1523.9% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #903 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #903 out of 921 companies for PB Ratio. This places Sanofi Consumer Healthcare India in the lower half of its industry. The industry median PB Ratio is 1.88. Sanofi Consumer Healthcare India's value of 30.53 is 1523.9% above this benchmark. Historically, Sanofi Consumer Healthcare India's own PB Ratio has ranged from 24.22 to 48.05 over the past decade. While the company's 10-year median is 39.69 vs. the industry median of 1.88, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current PB Ratio of 30.53 is 1523.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current PB Ratio is 30.53, which is 23% below median its own 10-year median of 39.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current PB Ratio of 30.53. The current PB Ratio is 30.53, which is 23% below median its 10-year median of 39.69 and 1523.9% above the Drug Manufacturers industry median of 1.88. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current PB Ratio is 30.53 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
